Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 3, No. 3, 1997
Issue release date: 1997
Section title: Special Topic Section: Craving and Anticraving
Eur Addict Res 1997;3:129–137
(DOI:10.1159/000259166)

Acamprosate and Prevention of Relapse in Alcoholics

Results of a Randomized, Placebo-Controlled, Double-Blind Study in Out-Patient Alcoholics in the Netherlands, Belgium and Luxembourg

Geerlings P.J.a · Ansoms C.b · van den Brink W.c
aDe Jellinek, Amsterdam, The Netherlands, bKliniek Breeders Alexianen, Tienen, Belgium, cAmsterdam Institute for Addiction Research, Amsterdam, The Netherlands

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Special Topic Section: Craving and Anticraving

Published online: November 11, 2009
Issue release date: 1997

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 1022-6877 (Print)
eISSN: 1421-9891 (Online)

For additional information: http://www.karger.com/EAR

Abstract

Acamprosate is registered in the Benelux for the treatment of alcohol dependence. In a randomised, placebo-controlled, double-blind study in 262 subjects from 22 treatment centres in the Benelux countries, the effect of acamprosate as a supplement to the existing out-patient psychosocial intervention was studied on relapse after detoxification over a period of 6 months. Acamprosate had a clear positive effect on relapse prevention. Subjects in the acamprosate group completed treatment more frequently (41 vs. 31 %) and on average remained in treatment for longer (102 vs. 88 days). Patients in the acamprosate group relapsed later (after 45 vs. 15 days), were abstinent longer (61 vs. 43 days) and were more often abstinent for the entire duration of the 6-month treatment (20 vs. 10%). In the acamprosate group, 11% consumed no alcohol throughout the study period, while in the placebo group this was the case only in 5%; however, on account of the small numbers, this difference was not statistically significant. The therapeutic advantage of the acamprosate-treated patients was still present 6 months after treatment. The drug was generally well tolerated, and no serious complications occurred during the study. A major problem was the large number of subjects in both the experimental as well as the control group who did not complete treatment. It is concluded that acamprosate could be a useful adjuvant to psychosocial treatment.

© 1997 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Special Topic Section: Craving and Anticraving

Published online: November 11, 2009
Issue release date: 1997

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 1022-6877 (Print)
eISSN: 1421-9891 (Online)

For additional information: http://www.karger.com/EAR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.